Inside informationEnglish
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Nanobiotix
- Filed
- 27/03/2025, 21:15
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 112438_20250327